Breathing medicines
Pro Research Analysisby 
Searched over 200M research papers for "breathing medicines"
Breathing Medicines: An Overview of Pharmacologic Treatments and Inhalation Therapies
Pharmacologic Agents for Sleep-Disordered Breathing
Pharmacologic treatments for sleep-disordered breathing have been extensively reviewed, focusing on various ventilatory stimulants, psychotropic drugs, and antihypertensive agents. Theophylline and opioid antagonist/nicotine groups have the most objective data available. Specific indications for ventilatory stimulants include medroxyprogesterone for hypercapnic obesity-hypoventilation, thyroid replacement for myxedema, acetazolamide for central apnea, and theophylline for periodic breathing in congestive heart failure. However, no single pharmacologic agent has proven effective for obstructive sleep apnea (OSA), highlighting the need for further controlled studies.
Suvorexant and Respiratory Function in COPD Patients
Suvorexant, an orexin receptor antagonist used for treating insomnia, was evaluated for its effects on breathing in patients with chronic obstructive pulmonary disease (COPD). In a randomized, double-blind, placebo-controlled study, suvorexant did not significantly affect oxygen saturation or the Apnea Hypopnea Index (AHI) in patients with mild-to-moderate COPD. These findings suggest that suvorexant, even at doses up to twice the maximum recommended for insomnia, does not have a clinically meaningful respiratory depressant effect in this patient population.
Anesthetics and Their Impact on Breathing
Research on the effects of anesthetics such as isoflurane, ketamine-xylazine, and urethane on breathing in mice has shown that these agents significantly reduce the hypercapnic ventilatory response (HCVR) even at subtherapeutic doses. These anesthetics also alter baseline breathing, indicating that their use in respiratory physiology studies may affect the interpretation of results due to their impact on breathing and CO2 chemoreception.
Promising Drug Combinations for Sleep Apnea
A new drug combination of atomoxetine and oxybutynin has shown promise in treating obstructive sleep apnea. In a study involving 20 patients, this combination significantly reduced the number of hourly airway obstructions, suggesting a potential alternative to traditional continuous positive airway pressure (CPAP) therapy.
Inhalation Therapies: Past, Present, and Future
Inhalation as a route of drug administration has evolved significantly, particularly for treating respiratory diseases like asthma and COPD. Inhaled medications, including β-2 receptor agonists, muscarinic acetylcholine receptor antagonists, glucocorticosteroids, and cromones, offer rapid action, low metabolism, and high bioavailability. Recent advancements have also enabled the systemic delivery of drugs via inhalation, such as inhaled insulin for diabetes, highlighting the potential for expanding the range of treatable conditions through this route .
Breathing Exercises for Asthma Management
Breathing exercises have been explored as a complementary therapy for asthma. Although individual studies have reported improvements in quality of life, asthma symptoms, and acute exacerbations, the overall evidence remains inconclusive due to methodological differences and poor reporting. Nonetheless, trends for improvement are encouraging, and further well-designed studies are needed to establish the efficacy of breathing exercises in clinical practice .
Conclusion
The landscape of breathing medicines encompasses a variety of pharmacologic agents and inhalation therapies, each with its own set of benefits and limitations. While certain drugs show promise for specific conditions, such as theophylline for periodic breathing in heart failure or the combination of atomoxetine and oxybutynin for sleep apnea, the need for further research is evident. Inhalation therapies continue to advance, offering new possibilities for both respiratory and systemic treatments. Breathing exercises also hold potential as a complementary therapy for asthma, though more robust evidence is required to confirm their efficacy.
Sources and full results
Most relevant research papers on this topic